LONDON (Alliance News) - Verona Pharma PLC on Tuesday said it secured a key patent from the European Patent Office relating to its lead development candidate, ensifentrine.
The clinical stage biopharmaceutical company added that the patent provides intellectual property protection across Europe until 2035 for a suspension formulation of ensifentrine suitable for nebulized administration.
The product is currently in phase 2b trials for for chronic obstructive pulmonary disease.
A corresponding patent has already been issued in the US.
Verona shares were flat at 60.00 pence each on Tuesday afternoon.